Effect of Nimotuzumab Combined with GP Chemotherapy in the Treatment of Metastatic Nasopharyngeal Carcinoma

doi:10.13438/j.cnki.jdzk.2022.06.012

Abstract

Abstract: The efficacy and adverse reactions of nituzumab combined with GP chemotherapy in the treatment of metastatic nasopharyngeal carcinoma has been analyzed.Patients diagnosed by the pathology and the imaging of advanced metastatic nasopharyngeal carcinoma from June 1,2019 to December 31,2020 in Xiangxi Autonomous Prefecture People's Hospital,and were randomly divided into experimental group (GP + Nimotuzumab)and control group (GP) .The effective rate,disease control rate,progression-free survival,overall survival and adverse reactions of the two groups were compared and analyzed.A total of 28 patients were included in this study,including 14 in the experimental group and 14 in the control group.In the experimental group there were 1 case of CR,10 cases of PR,2 cases of SD,and 1 case of PD;and in the control group,ORR of the experimental group and control group was 78.5% vs 50.0%(P=0.115),and DCR 92.8% vs 85.7%(P=0.541).The median DOR was 7 months in the experimental group and 5 in the control group (P=0.068).The median PFS of the experimental group and the control group were 11 months and 7 months (P=0.043).The median OS was 19 months in experimental group and 13 months in control group (P=0.043) .The main adverse reactions in both groups were myelosuppression,gastrointestinal reactions and hepatic injury.Degrees of myelosuppression occurred in 11 patients in the experimental group and in 12 in the control group (P=0.662).The rates of grade 1~2 myelosuppression in the two groups were 50.00% vs 25.00% (P=0.115),while 3~4 grade in the two groups were (33.33% vs 64.28%,P=0.058).Grade 1~2 gastrointestinal reactions occurred in both groups 35.71% vs 50.00% (P=0.445).The incidence of grade 1~2 hepatic injury was (21.43% vs 7.14%,P=0.280),and that of grade 3~4 hepatic injury was the same (7.14%) .Compared with GP alone,GP +Nimotuzumab did not improve the short-term efficacy in the treatment of advanced metastatic nasopharyngeal carcinoma,but prolonged the PFS time,improved the overall survival,and did not increase the adverse reactions.

Key words: metastatic nasopharyngeal carcinoma, nimotuzumab, GP treatment, effect

CHEN Jia, XIANG Zhibi, XIONG Li, DUAN Hexin, LIU Rong, YANG Zhi, WU Hui, YANG Zaichuan. Effect of Nimotuzumab Combined with GP Chemotherapy in the Treatment of Metastatic Nasopharyngeal Carcinoma[J]. Journal of Jishou University(Natural Sciences Edition), 2022, 43(6): 67-74.

References

[1] 梁锌,杨剑,高婷,等.中国鼻咽癌流行概况[J].中国肿瘤,2016,25(11):835-840.
[2] 肖震宇,邓江华.局部晚期鼻咽癌同期放化疗的临床疗效观察[J].肿瘤防治研究,2007(12):982.
[3] WEI WILLIAM I,SHAM JONATHAN S T.Nasopharyngeal Carcinoma[J].The Lancet,2005,365(9476):2041-2054.
[4] LEE ANNE W M,NG WAI TONG,CHAN LUCY L K,et al.Evolution of Treatment for Nasopharyngeal Cancer-Success and Setback in the Intensity-Modulated Radiotherapy Era[J].Radiotherapy and Oncology,2014,110(3):377-384.
[5] SETTON JEREMY,HAN JAMES,KANNARUNIMIT DANITA,et al.Long-Term Patterns of Relapse and Survival Following Definitive Intensity-Modulated Radiotherapy for Non-Endemic Nasopharyngeal Carcinoma[J].Oral oncology,2016,53:67-73.
[6] JIANG Feng,JIN Ting,FENG Xinglei,et al.Long-Term Outcomes and Failure Patterns of Patients with Nasopharyngeal Carcinoma Staged by Magnetic Resonance Imaging in Intensity-Modulated Radiotherapy Era:The Zhejiang Cancer Hospital's Experience[J].Journal of cancer research and therapeutics,2015,11(6):179-184.
[7] ZHANG Li,HUANG Yan,HONG Shaodong,et al.Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin in Recurrent or Metastatic Nasopharyngeal Carcinoma:A Multicentre,Randomised,Open-Label,Phase 3 Trial[J].The Lancet,2016,388(10054):1883-1892.
[8] YANG Yunpeng,QU Song,LI Jingao,et al.Camrelizumab Versus Placebo in Combination with Gemcitabine and Cisplatin as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN-1st):A Multicentre,Randomised,Double-Blind,Phase 3 trial[J].The Lancet Oncology,2021,22(8):1162-1174.
[9] PSYRRI AMANDA,SEIWERT TANGUY Y,JIMENO ANTONIO.Molecular Pathways in Head and Neck Cancer:EGFR,PI3K,and more[J].American Society of Clinical Oncology Educational Book,2013,33(1):246-255.
[10] 李燕巍,谢广茹,潘战宇.鼻咽癌的生物靶向治疗进展[J].临床耳鼻咽喉头颈外科杂志,2015,29(7):671-673.
[11] 庄文杰,柳春晖,司徒慧如,等.老年中晚期鼻咽癌患者尼妥珠单抗联合顺铂及5-氟尿嘧啶放化疗的临床研究[J].老年医学与保健,2016,22(5):309-312.
[12] ZHANG Zichen,FU Sha,WANG Feng,et al.Oncogene Mutational Profile in Nasopharyngeal Carcinoma[J].Onco Targets and Therapy,2014,7:457-467.
[13] VERMORKEN JAN B,MESIA RICARD,RIVERA FERNANDO,et al.Platinum-Based Chemotherapy Plus Cetuximab in Head and Neck Cancer[J].New England Journal of Medicine,2008,359(11):1116-1127.
[14] MESIA R,RIVERA F,KAWECKI A,et al.Quality of Life of Patients Receiving Platinum-Based Chemotherapy Plus Cetuximab First Line for Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck[J].Annals of Oncology,2010,21(10):1967-1973.
[15] GUO Ye,LUO Yi,ZHANG Qingyuan,et al.First-Line Treatment with Chemotherapy Plus Cetuximab in Chinese Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck:Efficacy and Safety Results of the Randomised,Phase III CHANGE-2 Trial[J].European Journal of Cancer,2021,156:35-45.
[16] GUIGAY JOL,AUPRIN ANNE,FAYETTE JRME,et al.Cetuximab,Docetaxel,and Cisplatin Versus Platinum,Fluorouracil,and Cetuximab as First-Line Treatment in Patients with Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma (GORTEC 2014-01 TPExtreme):A Multicentre,Open-Label,Randomised,Phase 2 Trial[J].The Lancet Oncology,2021,22(4):463-475.
[17] 郭晔,张陈平.抗EGFR单抗治疗复发/转移性头颈部鳞状细胞癌临床共识（2021年版）[J].中国癌症杂志,2021,31(12):1220-1232.
[18] YOU Rui,SUN Rui,HUA Yijun,et al.Cetuximab or Nimotuzumab Plus Intensity-Modulated Radiotherapy Versus Cisplatin Plus Intensity-Modulated Radiotherapy for Stage II-IVb Nasopharyngeal Carcinoma[J].International Journal of Cancer,2017,141(6):1265-1276.
[19] WANG Zhiqiang,MEI Qi,LI Jibin,et al.The Long-Term Survival of Patients with III-IVb Stage Nasopharyngeal Carcinoma Treated with IMRT with or Without Nimotuzumab:A Propensity Score-Matched Analysis[J].BMC Cancer,2019,19(1):1-12.
[20] 舒禹先.顺铂和5-氟脲嘧啶联合尼妥珠单抗作为一线方案治疗转移鼻咽癌的临床观察[J].实用癌症杂志,2016,31(12):2090-2092.
[21] Zhao C,Miao J,Shen G,et al.Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody combined with Cisplatin and 5-Fluorouracil in Patients with Metastatic Nasopharyngeal Carcinoma after Radical Radiotherapy:A Multicentre,Open-label,Phase II Clinical Trial[J].Annals of Oncology,2019,30(4):637-643.
[22] 陆颖,陈达桂,梁锦辉,等.尼妥珠单抗联合PF方案诱导治疗局部晚期鼻咽癌的多中心临床研究[J].肿瘤防治研究,2019,46(4):358-362.